PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91022F00027Fy22 - APA buildings - building 1 — Leidos Biomedical Research, Inc

Leidos Biomedical Research, Inc holds $2.1B across 186 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75N91019D00024. Recompete timing centers on the Feb 5, 2027 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci
Awarding office
Leidos Biomedical Research, Inc
Recipient
Feb 5, 2027
PoP end
$5.7M
Obligated
$5.9M
Potential
541715
NAICS
AN12
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Leidos Biomedical Research, Inc — $90

Contract facts

Federal
Contract number75N91022F00027
Also listed as75N91019D00024-75N91022F00027
AgencyNih Nci
Awarding officeNih Nci
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentLeidos Biomedical Research, Inc
CAGE3LYK6
UEIHV8BH9BPG8Y9
NAICS541715
PSCAN12
Parent IDIQ / IDV75N91019D00024
Place of performanceFREDERICK MD
Pricing typeCost Plus Fixed Fee
Extent competedFull And Open Competition
PoP startSep 20, 2022
PoP end (current)Feb 5, 2027
Obligated$5.7M
Current value$5.9M
Potential value$5.9M

FY22 - APA BUILDINGS - BUILDING 1 is a federal award for Nih Nci held by Leidos Biomedical Research, Inc. Estimated value $5.9M ($5.7M obligated). Current period of performance ends Feb 5, 2027. Place of performance: FREDERICK MD.

Recompete timing

Public
Expiring in 169 days

Current PoP ends Feb 5, 2027 (169 days remaining). Agencies typically plan 12–18 months ahead — at 5.6 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Leidos Biomedical Research, Inc$2.1B obligated across 186 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$2.1B · 100% of firm total
Open full company profile

Related awards

Same parent · incumbent
75N91021F00013
ENABLING NCI CLINICAL & RESEARCH DATA SHARING
$81.1M
Aug 31, 2026
75N91021F00006
FY21 CONSOLIDATED FACILITIES TASK ORDER C
$18.6M
Sep 4, 2026
75N91021F00017
ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT
$12.1M
Sep 15, 2026
75N91021F00016
DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS
$6.6M
Sep 15, 2026
75N91021F00018
INFRASTRUCTURE IMPROVEMENTS
$4.6M
Sep 24, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75N91022F00027?

75N91022F00027 (Fy22 - APA buildings - building 1) is a Nih Nci award with a potential value of $5.9M, currently held by Leidos Biomedical Research, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91022F00027?

Nih Nci awarded 75N91022F00027 to Leidos Biomedical Research, Inc (potential $5.9M).

Who is the incumbent on 75N91022F00027?

Leidos Biomedical Research, Inc is the incumbent with $2.1B across 186 related awards in SCOUT’s public footprint. The current period of performance ends Feb 5, 2027.

When does Leidos Biomedical Research, Inc’s 75N91022F00027 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 5, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N91022F00027